Trombocitopenia inmunitaria, como efecto adverso a vacuna frente a COVID-19, descripción de dos casos y revisión de bibliografía

  1. Ángel Martínez González 1
  2. Irea Vidal González 2
  3. Laura Fernández González 2
  4. María Díaz Redonet 3
  5. Manuella González Nunes 4
  1. 1 Servicio de Urgencias. Hospital Ribera-Povisa de Vigo. Pontevedra (España)
  2. 2 Servicio de Medicina Interna. Hospital Ribera-Povisa de Vigo. Pontevedra (España)
  3. 3 Servicio de Medicina Familiar y Comunitaria. Complejo Hospitalario Universitario de Vigo. Pontevedra (España)
  4. 4 Complejo Hospitalario Universitario de Pontevedra (España)
Show affiliations +
Journal:
Revista Clínica de Medicina de Familia

ISSN: 2386-8201

Year of publication: 2024

Volume: 17

Issue: 1

Pages: 80-82

Type: Article

DOI: 10.55783/RCMF.170112 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista Clínica de Medicina de Familia

Abstract

Drug-induced thrombocytopenia (DITP) is an acquired thrombocytopenia due to drug-dependent platelet-reactive antibodies causing platelet destruction. Since the onset of vaccination for SARS-CoV-2, cases of different adverse effects have been appearing. Among the most notorious is immune thrombopenic thrombosis. We report two patients with isolated thrombocytopenia with a history of vaccination for COVID19 in the previous weeks as the triggering event; after having performed a full study that ruled out other possible aetiologies, as well as a bibliographic review on this entity.

€ View funding

Funding information

Funders

Bibliographic References

  • Cecinati V, Principi N, Brescia L, Giordano P, Esposito S. Vaccine administration and the development of immune thrombocytopenic purpura in children. Human vaccines & immunotherapeutics 2013;9(5):1158-1162.
  • Cines DB, Liebman H, Stasi R. Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009;46(1 Suppl 2):S2-14.
  • Marcucci R, Marietta M. Vaccine-induced thrombotic thrombocytopenia: the elusive link between thrombosis and adenovirus-based SARS-CoV-2 vaccines. Internal and Emergency Medicine 2021:1-7.
  • Mitta A, Curtis BR, Reese JA, George JN. Drug-induced thrombocytopenia: 2019 update of clinical and laboratory data. Am J Hematol 2019;94(3):E76-E78.
  • Pishko AM, Bussel JB, Cines DB. COVID-19 vaccination and immune thrombocytopenia. Nat Med. 2021:1-2.
  • Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021:1-8.
  • Tarawneh O, Tarawneh H. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am J Hematol. 2021.
  • Tiede A, Sachs UJ, Czwalinna A, Werwitzke S, Bikker R, Krauss JK, et al. Prothrombotic immune thrombocytopenia after COVID-19 vaccination. Blood, The Journal of the American Society of Hematology 2021;138(4):350-353.
  • Vayne C, Guéry E, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. Journal of Clinical Medicine 2020;9(7):2212.
  • Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
Data source: Dialnet